Search Within

Shanu Modi

  1. "Biostatistics Service"
Formats
  1. Journal Article (34)
  2. Meeting Abstract (32)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (67)
  2. Breast Medicine Service (67)
  3. Department of Medicine (67)
  4. Epidemiology and Biostatistics (67)
  5. Solid Tumor Oncology Division (67)
  6. Survivorship Research (61)

More Groups

People
  1. Clifford Hudis (44)
  2. Sujata Patil (44)
  3. Larry Norton (32)
  4. Sarat Chandarlapaty (28)
  5. Chau Dang (25)
  6. Gabriella D'Andrea-Carlino (23)

More People

Years
  1. 2025 (1)
  2. 2024 (5)
  3. 2023 (4)
  4. 2022 (5)
  5. 2021 (3)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Cancer Research (14)
  3. Clinical Breast Cancer (6)
  4. Clinical Cancer Research (4)
  5. npj Breast Cancer (4)
  6. Breast Cancer Research and Treatment (2)

More Publications

Publishers
  1. American Association for Cancer Research (20)
  2. American Society of Clinical Oncology (17)
  3. Elsevier Inc. (9)
  4. Nature Publishing Group (6)
  5. Oxford University Press (4)
  6. Springer (3)

More Publishers

Results (67)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The epichaperome is an integrated chaperome network that facilitates tumour survival
    Journal Article

    Rodina, A.; Wang, T.; Yan, P.; Gomes, E. D.; Dunphy, M. P. S.; Pillarsetty, N.; Koren, J. 3rd; Gerecitano, J. F.; Taldone, T.; Zong, H.; more...
    Nature (2016)

    Fulltext@MSK | Save
  • Biomarkers that predict sensitivity to heat shock protein 90 inhibitors
    Journal Article

    Jhaveri, K.; Chandarlapaty, S.; Iyengar, N.; Morris, P. G.; Corben, A. D.; Patil, S.; Akram, M.; Towers, R.; Sakr, R. A.; King, T. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience
    Meeting Abstract

    Singh, J. C.; Sugarman, S.; Jones, L.; Boafo, C.; Patil, S.; Schweber, S.; Yu, A.; Argolo, D.; Modi, S.; Iyengar, N.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; Haque, S.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer
    Journal Article

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S. M.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G. M.; Drullinsky, P. R.; Gajria, D.; Goldfarb, S. B.; Comen, E. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation
    Journal Article

    Yang, T. J.; Morrow, M.; Modi, S.; Zhang, Z.; Krause, K.; Siu, C.; McCormick, B.; Powell, S. N.; Ho, A. Y.
    Annals of Surgical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Dickler, M. N.; Ulaner, G.; Zamora, S. J.; Sterlin, V.; Iasonos, A.; Coughlin, C. M.; Morozov, A.; Ero, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Ulaner, G.; Zamora, S.; Sterlin, V.; Iasonos, A.; Dickler, M. N.; Moynahan, M. E.; Hudis, C. A.; Baselga, J.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save